10.1172/JCI97233 Summary Keywords obsessive-compulsive disorder, autism, glucagon-like peptide-1 agonist, intellectual disability, weight, overeating Citation Jrvinen A, Laine MK, Tikkanen R and Castrn ML (2019) Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism
Participants who started at 2 mg (lower starting dose) experienced fewer GI side effects than those who started at 4 mg, even when both groups eventually reached the same maintenance dose
View AOD-9604 The peptide was developed by Metabolic Pharmaceuticals (Melbourne, Australia) specifically to isolate the fat-metabolism activity of the GH C-terminal domain while avoiding the growth-promoting and insulin-sensitizing effects of full-length GH
For a related look at the daily oral format, read our guide on whether tirzepatide comes in pill form
Our team will assist you in verifying your coverage and exploring options to minimize out-of-pocket costs